Gilead Sciences appoints new haematology and oncology head

Gilead Sciences has announced the appointment of Alessandro Riva as its new senior vice-president and head of its haematology and oncology therapeutic areas.

Dr Riva joins Gilead from Novartis Oncology, where he served as head of global oncology development, playing a key role in the creation of more than 20 cancer compounds, including several targeted and immune-oncology therapies.

Prior to his 12-year tenure at Novartis, he co-founded the Breast Cancer International Research Group and Cancer International Research Group, with other previous employers including Farmitalia Carlo Erba, Rhone-Poulenc and Aventis.

The expert has authored or co-authored more than 100 oncology research manuscripts and abstracts during his career and will now take charge of haematology and oncology programmes at Novartis.

Dr John McHutchison, executive vice-president for clinical research at Gilead Sciences, said: "His leadership and proven track record developing therapies across the spectrum of haematological malignancies and solid tumours will be instrumental as we continue to grow and advance our pipeline of novel therapeutics for people living with cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.